140639-94-7

Upstream product

• 68348-23-2 3-(1,3-dioxolan-2-yl)benzaldehyde 
• 626-19-7 Isophthalaldehyde 
• 52178-50-4 Methyl 3-formylbenzoate 
• 17789-14-9 3-(1,3-dioxolan-2-yl)-phenylbromide 
• 124791-75-9 methyl 4-(2,2-dimethoxyethyl)benzoate 
• 119770-37-5 methyl 4-[(E)-2-methoxyethenyl]benzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 124038-36-4 3-[1,3]Dioxolan-2-yl-benzoic acid methyl ester 
• 107-21-1 ethylene glycol 

Downstream Products

• 28746-20-5 3-(methoxymethyl)benzaldehyde 
• 52010-98-7 3-(hydroxymethyl)benzaldehyde 
• 922525-34-6 C₁₂H₁₇NO 
• 203940-48-1 methyl 4-({[1-(3-hydroxymethylphenyl)-2-nitroethyl]thio}methyl)benzoate 
• 203940-49-2 methyl (±)-4-({[2-amino-1-(3-hydroxymethylphenyl)ethyl]thio}methyl)benzoate 
• 203940-25-4 (+/-)-methyl 4-{[(2-{4-chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 
• 203940-51-6 methyl 4-({[2-(4-chlorophenylsulfonylamino)-1-(3-formylphenyl)ethyl]thio}methyl)benzoate 
• 203940-50-5 methyl 4-({[2-(4-chlorophenylsulfonylamino)-1-(3-hydroxymethylphenyl)ethyl]thio}methyl)benzoate 

Relevant academic research and scientific papers

Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) and steroid sulfatase (STS) are involved in the synthesis of the most potent estrogen in the human body, estradiol (E2). These enzymes are known to play a pivotal role in the progression of estrogen-depen

Muscarinic receptor m3 antagonist/beta2-adrenergic receptor stimulant bridge ring derivatives

The invention relates to bridged ring compounds shown in a general formula (III) and having dual activities of muscarinic receptor M3 antagonism and beta2-adrenergic receptor stimulation, or stereoisomers, hydrates, metabolites, solvates, pharmaceutically acceptable salts, eutectic crystals or prodrugs thereof. The invention also relates to a preparation method and application of the compounds inpreparation of drugs for treating airway obstruction diseases. Each substituent in the general formula (III) is as defined in the specification.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

Synthesis of optically active thromboxane A2 and Leukotriene D4 receptor antagonists

Both (+)- and (-)-4-{[(2-{4-cUorophenylsulfonylamino}-1-{3-[(Q-2-(7-cWoro- 2-quinolyl)-vinyl]phenyl}ethyl)-thio]methyl}benzoic acid (1), Thromboxane A2 and Leukotriene D4 receptor dual antagonist were synthesized. Racemic methyl 4-({[2-amino-1-(3-hydroxym

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

CBI analogues of the duocarmycins and CC-1065

An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≧1000-fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC50=2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. The increases in cytotoxicity correlate well with accompanying increases in the rate and efficiency of DNA alkylation. This effect is more pronounced with the CBI versus DSA or CPI based analogues. Moreover, this effect is largely insensitive to the electronic character of the C5 substituent but is sensitive to the size, rigid length, and shape (sp, sp2, sp3 hybridization) of this substituent consistent with expectation that the impact is due simply to its presence.

Synthesis of a Spheroidal Bis-porphyrin: a Ligand Designed to Accept Two Catalytic Metal Ions in an Isolated Environment

A spheroidal bis-porphyrin (dual capped quadruply cofacial dimeric tetraphenylporphyrin, 1), designed to be employed as a ligand for a class of catalysts that mimic the combined enzyme activities of superoxide dismutase and catalase, has been synthesized

Certain indole derivatives useful as leukotriene antagonists

A compound of the formula STR1 in which R1 is hydrogen, halo, C1-4 alkyl, C1-4 alkoxy, nitrile, optionally protected carboxy, optionally protected tetrazolyl, trihalomethyl, hydroxy-C1-4 alkyl, aldehydo, --CH2 Z, --CH=CH--Z or --CH2 CH2 Z where Z is optionally protected carboxy or optionally protected tetrazolyl; R2 is halo, nitrile, an optionally protected acid group or --CONR7 R8 where R7 and R8 are each hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen, C1-4 alkyl, optionally substituted phenyl, or C1-4 alkyl substituted by --CONR7 R8 or an optionally protected acid group; R5 is STR2 where W is --CH=CH--, --CH=N--, --N=CH--, --O-- or --S--, R9 is hydrogen, halo, C1-4 alkyl, C1-4 alkoxy or trihalomethyl, and R10 is hydrogen, C1-4 alkyl, C2-6 alkenyl, C3-6 cycloalkyl or C1-4 alkyl-C3-6 cycloalkyl; R6 is hydrogen or C1-4 alkyl; X is --O--(CH2)n CR11 R12, --CR11 R12 --, --CR11 R12.(CH2)n.CR13 R14 -- or --CR11 =CR12 -- where R11, R12, R13 and R14 are each hydrogen or C1-4 alkyl, and n is 0, 1 or 2; and Y is --O--CR15 R16 --, --CR15 =CR16 -- or --CR15 R16.CR17 R18 -- where R15, R16, R17 and R18 are each hydrogen or C 1-4 alkyl; or a salt thereof. The compounds in unprotected form are active as leukotriene antagonists.